open access

Vol 26, No 3 (2019)
Original articles — Clinical cardiology
Published online: 2018-03-02
Get Citation

Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome

Sai Lv, Wei Liu, Yujie Zhou, Yuyang Liu, Dongmei Shi, Yingxin Zhao, Xiaoli Liu, Jumana W. Alhelal, K.S. Shakeenah Ravuru
DOI: 10.5603/CJ.a2018.0022
·
Pubmed: 29512091
·
Cardiol J 2019;26(3):275-282.

open access

Vol 26, No 3 (2019)
Original articles — Clinical cardiology
Published online: 2018-03-02

Abstract

Background: Coronary artery disease (CAD) in adults 35 years of age is rare, but the incidence is on the rise and the risk factors for this age group are largely uncertain. Previous studies have shown that hyperuricemia (HUA) is an independent risk factor for CAD in the general population, whereas the role in adults 35 years of age with acute coronary syndrome (ACS) is unclear.

Methods: Patients, 18–35 years of age, diagnosed with ACS for the first time at the documented institu- tion between January 2005 and December 2015, were enrolled in the current study. The severity of CAD was assessed by the Gensini score. Patients were divided into two groups according to the definition of HUA. The relationship between HUA and CAD severity was assessed based on multi-variate analysis. 

Results: Seven hundred seventy-one participants fulfilling the criteria were included in this study (mean age, 31.6 years; 94.4% male). HUA, which was defined as a serum uric acid level 7.0 mg/dL (420μmol/L) in males and 6.0 mg/dL (357 μmol/L) in females, accounted for 37% of the participants. Multivariate analysis identified that HUA is an independent risk factor of CAD severity, as assessed by the Gensini score, in very young adults with ACS (OR 8.28; 95% CI 1.96–14.59; p = 0.01), and the effect of HUA on CAD severity was second only to diabetes mellitus.

Conclusions: Hyperuricemia was shown to be an independent risk factor for CAD severity in young adults with ACS (18–35 years of age).

Abstract

Background: Coronary artery disease (CAD) in adults 35 years of age is rare, but the incidence is on the rise and the risk factors for this age group are largely uncertain. Previous studies have shown that hyperuricemia (HUA) is an independent risk factor for CAD in the general population, whereas the role in adults 35 years of age with acute coronary syndrome (ACS) is unclear.

Methods: Patients, 18–35 years of age, diagnosed with ACS for the first time at the documented institu- tion between January 2005 and December 2015, were enrolled in the current study. The severity of CAD was assessed by the Gensini score. Patients were divided into two groups according to the definition of HUA. The relationship between HUA and CAD severity was assessed based on multi-variate analysis. 

Results: Seven hundred seventy-one participants fulfilling the criteria were included in this study (mean age, 31.6 years; 94.4% male). HUA, which was defined as a serum uric acid level 7.0 mg/dL (420μmol/L) in males and 6.0 mg/dL (357 μmol/L) in females, accounted for 37% of the participants. Multivariate analysis identified that HUA is an independent risk factor of CAD severity, as assessed by the Gensini score, in very young adults with ACS (OR 8.28; 95% CI 1.96–14.59; p = 0.01), and the effect of HUA on CAD severity was second only to diabetes mellitus.

Conclusions: Hyperuricemia was shown to be an independent risk factor for CAD severity in young adults with ACS (18–35 years of age).

Get Citation

Keywords

coronary artery disease; hyperuricemia; Gensini score; severity; young adults

About this article
Title

Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome

Journal

Cardiology Journal

Issue

Vol 26, No 3 (2019)

Pages

275-282

Published online

2018-03-02

DOI

10.5603/CJ.a2018.0022

Pubmed

29512091

Bibliographic record

Cardiol J 2019;26(3):275-282.

Keywords

coronary artery disease
hyperuricemia
Gensini score
severity
young adults

Authors

Sai Lv
Wei Liu
Yujie Zhou
Yuyang Liu
Dongmei Shi
Yingxin Zhao
Xiaoli Liu
Jumana W. Alhelal
K.S. Shakeenah Ravuru

References (31)
  1. Maroszyńska-Dmoch EM, Wożakowska-Kapłon B. Clinical and angiographic characteristics of coronary artery disease in young adults: a single centre study. Kardiol Pol. 2016; 74(4): 314–321.
  2. Bhardwaj R, Kandoria A, Sharma R. Myocardial infarction in young adults-risk factors and pattern of coronary artery involvement. Niger Med J. 2014; 55(1): 44–47.
  3. Kalra S, Duggal S, Valdez G, et al. Review of acute coronary syndrome diagnosis and management. Postgrad Med. 2008; 120(1): 18–27.
  4. Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22): 2089–2099.
  5. Liu LS. Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39(7): 579–615.
  6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7): 539–553, doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
  7. Zhou J, Zhou Q, Wang DP, et al. Joint committee issued Chinese guideline for the management of dyslipidemia in adults. [ST-segment elevation myocardial infarction in the eastern urban China: from 2001 to 2011]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016; 44(4): 303–308.
  8. Thomas GN, Ho SY, Janus ED, et al. Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract. 2005; 67(3): 251–257.
  9. Kanbay M, Solak Y, Dogan E, et al. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif. 2010; 30(4): 288–295.
  10. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983; 51(3): 606.
  11. Liu J, Zuo SW, Li Y, et al. Hyperhomocysteinaemia is an independent risk factor of abdominal aortic aneurysm in a Chinese Han population. Sci Rep. 2016; 6: 17966.
  12. Kim SY, Guevara JP, Kim KMi, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(2): 170–180.
  13. Braga F, Pasqualetti S, Ferraro S, et al. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin Chem Lab Med. 2016; 54(1): 7–15.
  14. Duran M, Kalay N, Akpek M, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology. 2012; 63(6): 448–452.
  15. Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia and the risk for subclinical coronary atherosclerosis--data from a prospective observational cohort study. Arthritis Res Ther. 2011; 13(2): R66.
  16. Zhang Jw, He Lj, Cao Sj, et al. Association of serum uric acid and coronary artery disease in premenopausal women. PLoS One. 2014; 9(9): e106130.
  17. Dai XM, Wei L, Ma LL, et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015; 34(9): 1605–1611.
  18. Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99(11): 759–766.
  19. Volterrani M, Iellamo F, Sposato B, et al. Uric acid lowering therapy in cardiovascular diseases. Int J Cardiol. 2016; 213: 20–22.
  20. Zuo T, Liu X, Jiang Lu, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016; 16(1): 207.
  21. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
  22. Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013; 19(13): 2432–2438.
  23. Klinenberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron. 1975; 14(1): 88–98.
  24. Wu L, Yang LJ, Meng XY, et al. Association between hyperuricemia and outcomes in patients undergoing percutaneous coronary intervention. Int J Cardiol. 2016; 204: 152–153.
  25. Biscaglia S, Ceconi C, Malagù M, et al. Uric acid and coronary artery disease: An elusive link deserving further attention. Int J Cardiol. 2016; 213: 28–32.
  26. Puddu P, Puddu GM, Cravero E, et al. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012; 59(3): 235–242.
  27. Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016; 6: 19520.
  28. pmhdev. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis - National Library of Medicine - PubMed Health. Centre for Reviews & Dissemination. ; 2012.
  29. Wolfe C, Vacek J. Myocardial Infarction in the Young. Chest. 1988; 94(5): 926–930.
  30. Christus T, Shukkur AM, Rashdan I, et al. Coronary Artery Disease in Patients Aged 35 or less - A Different Beast? Heart Views. 2011; 12(1): 7–11.
  31. Sinning C, Lillpopp L, Appelbaum S, et al. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol. 2013; 102(7): 495–503.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl